Cargando…

Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as ‘pigmented villonodular (teno)synovitis’ is characterized by local aggres...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebuzzi, Sara Elena, Grassi, Massimiliano, Catalano, Fabio, Buscaglia, Michele, Bertulli, Rossella, Satragno, Camilla, Belgioia, Liliana, Comandini, Danila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903349/
https://www.ncbi.nlm.nih.gov/pubmed/31567307
http://dx.doi.org/10.1097/CAD.0000000000000844
_version_ 1783477836548407296
author Rebuzzi, Sara Elena
Grassi, Massimiliano
Catalano, Fabio
Buscaglia, Michele
Bertulli, Rossella
Satragno, Camilla
Belgioia, Liliana
Comandini, Danila
author_facet Rebuzzi, Sara Elena
Grassi, Massimiliano
Catalano, Fabio
Buscaglia, Michele
Bertulli, Rossella
Satragno, Camilla
Belgioia, Liliana
Comandini, Danila
author_sort Rebuzzi, Sara Elena
collection PubMed
description Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as ‘pigmented villonodular (teno)synovitis’ is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour.
format Online
Article
Text
id pubmed-6903349
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-69033492020-01-22 Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour Rebuzzi, Sara Elena Grassi, Massimiliano Catalano, Fabio Buscaglia, Michele Bertulli, Rossella Satragno, Camilla Belgioia, Liliana Comandini, Danila Anticancer Drugs Case Reports Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as ‘pigmented villonodular (teno)synovitis’ is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour. Lippincott Williams & Wilkins 2020-01 2019-12-06 /pmc/articles/PMC6903349/ /pubmed/31567307 http://dx.doi.org/10.1097/CAD.0000000000000844 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Reports
Rebuzzi, Sara Elena
Grassi, Massimiliano
Catalano, Fabio
Buscaglia, Michele
Bertulli, Rossella
Satragno, Camilla
Belgioia, Liliana
Comandini, Danila
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
title Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
title_full Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
title_fullStr Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
title_full_unstemmed Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
title_short Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
title_sort multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903349/
https://www.ncbi.nlm.nih.gov/pubmed/31567307
http://dx.doi.org/10.1097/CAD.0000000000000844
work_keys_str_mv AT rebuzzisaraelena multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour
AT grassimassimiliano multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour
AT catalanofabio multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour
AT buscagliamichele multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour
AT bertullirossella multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour
AT satragnocamilla multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour
AT belgioialiliana multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour
AT comandinidanila multiplesystemictreatmentoptionsinapatientwithmalignanttenosynovialgiantcelltumour